PTH-glycine structure
|
Common Name | PTH-glycine | ||
---|---|---|---|---|
CAS Number | 2010-15-3 | Molecular Weight | 192.23800 | |
Density | 1.39g/cm3 | Boiling Point | 292.1ºC at 760mmHg | |
Molecular Formula | C9H8N2OS | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 130.5ºC | |
Symbol |
GHS06 |
Signal Word | Danger |
Name | pth-glycine |
---|---|
Synonym | More Synonyms |
Density | 1.39g/cm3 |
---|---|
Boiling Point | 292.1ºC at 760mmHg |
Molecular Formula | C9H8N2OS |
Molecular Weight | 192.23800 |
Flash Point | 130.5ºC |
Exact Mass | 192.03600 |
PSA | 64.43000 |
LogP | 1.30150 |
Index of Refraction | 1.684 |
Storage condition | −20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301-H311-H331 |
Precautionary Statements | P261-P280-P301 + P310-P311 |
Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
Hazard Codes | T: Toxic; |
Risk Phrases | 23/24/25 |
Safety Phrases | S36/37/39-S45 |
RIDADR | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | MU4025000 |
Packaging Group | III |
Hazard Class | 6.1(b) |
HS Code | 2933990090 |
Precursor 8 | |
---|---|
DownStream 6 | |
HS Code | 2933990090 |
---|---|
Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
J. Biol. Chem. 288(27) , 19359-69, (2013) Despite the fact that androgen deprivation therapy (ADT) can effectively reduce prostate cancer (PCa) size, its effect on PCa metastasis remains unclear. We examined the existing data on PCa patients ... |
|
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Cancer Res. 73(9) , 2926, (2013)
|
|
Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
J. Steroid Biochem. Mol. Biol. 145 , 144-56, (2015) Recently two drugs, namely the antiandrogen MDV-3100 and the inhibitor of 17α-hydroxylase abiraterone have been accepted by the FDA for the treatment of castration-resistant prostate cancer (CRPC) wit... |
3-phenyl-2-thio-hydantoi |
3-(phenyl)-2-thioxo-4-imidazolidinone |
3-PHENYL-2-THIOXO-4-IMIDAZOLIDINONE |
3-Phenyl-2-thiohydantoin |
3-phenyl-2-thioguidanthion |
glycine,3-phenyl-2-thiohydantoin |
EINECS 217-927-3 |
PHENYLTHIOHYDANTOIN-DL-GLYCINE |
(E)-2-cyano-3-(4-fluorophenyl)prop-2-enethioamide |
PHENYLTHIOHYDANTOIN-GLYCINE |
1-phenyl-2-thiohydantoin |
phenylthiohydantoin |
3-phenyl-2-thioxotetrahydro-4H-imidazol-4-one |
PTH-DL-GLYCINE |
3-phenyl-2-thioxoimidazolidin-4-one |
MFCD00027413 |